| Randall E. Millikan, PhD, MD |
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Office Address
The University of Texas MD Anderson Cancer Center
1155 Pressler St.
Unit Number: 1374
Houston, TX 77030
Room Number: CPB7.3462
Phone: 713-563-7245
Fax: 713-745-1625
1155 Pressler St.
Unit Number: 1374
Houston, TX 77030
Room Number: CPB7.3462
Phone: 713-563-7245
Fax: 713-745-1625
Education & Training
Degree-Granting Education | |
| 1988 | University of Miami, Miami, FL, MD, Medicine |
| 1985 | University of Chicago, Chicago, IL, PHD, Synthetic Organic Chemistry |
| 1980 | Wheaton College, Wheaton, IL, BS, Chemistry |
Postgraduate Training | |
| 1991-1994 | Clinician-Investigator Trainee in Medical Oncology, Clinician-Investigator Trainee in Medical Oncology, Mayo Clinic & Foundation, Rochester, MN |
| 1988-1/1991 | Internal Medicine, Internal Medicine, Mayo Graduate School of Medicine, Rochester, MN |
| 7/1985-6/1986 | Postdoctoral Fellow, Synthetic Organic Chemistry, Harvard University, Cambridge, MA, Professor E. J. Corey |
Experience/Service
Academic Appointments
Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 7/1994-9/2002
Administrative Appointments/Responsibilities
Medical Director, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 9/2003-12/2005
Institutional Committee Activities
Member, Research & Education IS Steering Team, 2005-present
Member, Clinical & Research Informatics Committee, 2005-present
Member, Clinical Research Committee, 1995-2001
Honors and Awards
| 2008 | caBIG Teamwork Award, National Cancer Institute |
| 1995 | Career Development Award, American Cancer Society |
| 1993 | American Cancer Society Clinical Oncology Fellow, American Cancer Society |
| 1993 | Keck Fellow in Biophysical Sciences |
| 1991 | Clinician-Investigator Award in Medical Oncology, Mayo Graduate School |
| 1990 | Finalist, Associates Clinical Vignette Competition of the American College of Physicians, American College of Physicians |
Selected Publications
Peer-Reviewed Original Research Articles | ||
| 1. | Svatek RS, Shariat SF, Lasky RE, Skinner EC, Novara G, Lerner SP, Fradet Y, Bastian PJ, Kassouf W, Karakiewicz PI, Fritsche HM, Muller SC, Izawa JI, Ficarra V, Sagalowsky AL, Schoenberg MP, Siefker-Radtke AO, Millikan RE, Dinney CP. The Effectiveness of Off-Protocol Adjuvant Chemotherapy for Patients with Urothelial Carcinoma of the Urinary Bladder. Clin Cancer Res 16(17):441-7, 9/2010. PMID: 20651056. | |
| 2. | Jonasch E, Wood CG, Matin SF, Tu SM, Pagliaro LC, Corn PG, Aparicio A, Tamboli P, Millikan RE, Wang X, Araujo JC, Arap W, Tannir N. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 27(25):4076-81, 9/2009. PMID: 19636008. | |
| 3. | Montero A, Diaz-Montero C, Millikan R, Liu J, Do D-A, Hodges S, Jonasch E, McIntyre B, Hwu P, Tannir N. Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon-(alpha): association of pretreatment serum levels with survival. Ann Oncol 20(10):1682-7, 6/2009. PMID: 19541791. | |
| 4. | Millikan RE, Wen S, Pagliaro LC, Brown MA, Moomey B, Do K-A, Logothetis CJ. Phase III trial of androgen ablation with or without 3 cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol 26(36):5936-42, 12/2008. PMID: 19029421. | |
| 5. | Thall PF, Logothetis C, Pagliaro LC, Wen S, Brown MA, Williams D, Millikan RE. Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens. J Natl Cancer Inst 99(21):1613-22, 11/2007. PMID: 17971530. | |
| 6. | Thall PF, Millikan RE, Meuller P, Lee SJ. Dose Finding with Two Agents in Phase 1 Oncology Trials. Biometrics 59(3):487-96, 9/2003. PMID: 14601749. | |
| 7. | Millikan RE, Dinney C, Swanson D, Sweeney P, Ro JY, Smith TL, Williams D, Logothetis C. Integrated Therapy for Locally Advanced Bladder Cancer. Final Report of a Randomized Trial of Cyctectomy plus Adjuvant M-VAC vs. Cystectomy with both Pre-andPost-Operative M-VAC. J Clin Oncol 19(20):4005-13, 2001. | |
| 8. | Thall PF, Millikan RE, Sung H. Evaluating Multiple Treatment Courses in Clinical Trials. Stat Med 19(8):1011-28, 4/2000. PMID: 10790677. | |
Abstracts | ||
| 1. | Siefker-Radtke AO, Kamat AM, Williams DL, Tannir NM, Tu S, Pagliaro LC, Dinney CP, Millikan RE. A Phase II Randomized 4-Regimen Selection Trial Incorporating Response for Sequential Chemotherapy in Metastatic, Unresectable Urothelial Cancer: Final Results from M.D. Anderson Cancer Center. 2009 Genitourinary Cancers Symposium Proceedings(238):198, 2/2009. | |
| 2. | Chiong E, Taylor JM, Siefker-Radtke AO, Millikan RE, Urbauer D, McConkey DJ, Grossman HB, Dinney CP, Kamat AM. Micropappilary Bladder Cancer: Comparison of Outcomes with Up Front Cystectomy and Neoadjuvant Chemotherapy. 2009 ASCO Genitourinary Symposium Proceedings (#255), 2009. | |
| 3. | Black P, Dinney CP, Brown GA, Kassouf W, Millikan RE, Siefker-Radtke AO, Munsell MF, Grossman H, Kamat AH. Radical cystoprostatectomy in patients with clinical T4b bladder cancer. 2008 ASCO Genitourinary Cancers Symposium Proceedings (#311), 2008. | |
| 4. | Siefker-RAdtke AO, Kamat AM, Grossman H, Williams DL, Dinney CP, Millikan RE. Final results from a phase II trial of systemic chemotherapy in a small cell urothelial cancer: Evidence supporting neoadjuvant chemotherapy from the M. D. Anderson Cancer Center. 2007 ASCO Annual Meeting Proceedings Park I 25(18S) (#5083), 2007. | |
| 5. | Rodney AJ, Siefker-Radtke A, Tannir NM, Swisher S, Walsh G, Millikan RE, Pagliaro LC. Treatment outcomes of patients (pts) with primary mediastinal germ cell tumors (PMGCT): The M. D. Anderson Cancer Center (MDACC) experience. 2006 ASCO Annual Meeting Proceedings Part I 24(18S) (#14538), 2006. | |
| 6. | Siefker-Radtke AO, Thall PF, Tannir NM, Tu S-M, Pagliaro LC, Williams DL, Millikan RE. Implementation of a novel statistucal design to ealuate successive treatment courses for metastatic transitional cell carcinoma. A Phase II trial at the M. D. Anderson Cancer Center. 2004 ASCO Annual Meeting Proceedings 22(14S) (#4543), 7/2004. | |
| 7. | Leibovici D, Millikan RE, Grossman HB, Dinney CP, Dong Q, Wu X. The pharmacogenetic impact of inflammatory genes on bladder cancer recurrence. AACR Meeting Abstracts 484 (#2105), 3/2004. | |
| 8. | Tannir NM, Wang X, NGg CS, Poulter VA, Mathew P, Siefker-Radtke AO, Jonasch E, Pagliaro LC, Cohen L. Millikan RE. A randomized phase III Trial of low dose versus intermediate dose interferon alfa (IFN) as front-line therapy in advanced progressive renal cell cancer (RCC). 2004 ASCO Annual Meeting Proceedings 22(14S) (#4607), 2004. | |
| 9. | Millikan RE, Thall P, Pagliaro L, Williams D, Brown M, Logothetis C. Randomized, adaptive, phase II selection trial of four chemotherpay regimens in androgen independent prostate cancer (AIPC). 2004 ASCO Annual Meeting Proceedings 22(14S) (#4561), 2004. | |
Book Chapters | ||
| 1. | Siefker-Radtke AO, Dinney CP, Czerniak B, Millikan RE. Bladder Cancer. In: M.D. Anderson Manual of Clinical Oncology. McGraw-Hill, 739-756, 2006. | |
| 2. | Siefker-Radtke A, Czerniak B, Dinney C, Millikan R. Uncommon Cancer of the Bladder. In: Texbook of Uncommon Cancer, Third Edition. Ed(s) D. Raghavan, M.L. John Wiley and Sons, 2006. | |
| 3. | Millikan RE, Hall S. New Posibilities in Systemic treatment for Metastic Bladder Cancer. In: Current Clinical Oncology; Bladder Cancer: Current Diagnosis and Treatment. Humana Press Inc., 393-422, 2001. | |
| 4. | Millikan RE, Thall PF. Statistical Considerations in the Phase II Evaluation of New Therapies. In: Current Clinical Urology: Bladder Cancer: Current Diagnosis and Treatment. Ed(s) Michael J. Droller. Humana Press: Totowa, NJ, 423-438, 2001. | |
| 5. | Millikan RE. Carcinoma of the Prostate. In: Current Therapy in Cancer. Ed(s) John F Foley, Julie M. Vose, James O. Armitage, 175-183, 1999. | |
| 6. | Agop P, Millikan RE. The University of Texas M.D. Anderson Cancer Center and The Journal Oncology Chapter. In: A Comphrensive Review. 26, 419-31, 1996. | |
Grant & Contract Support
| Title: | Specimen Core |
| Funding Source: | NIH/NCI |
| Role: | Co-Director |
| Principal Investigator: | Logothetis |
| Duration: | 7/1/2009 - 6/30/2010 |
| Title: | SPORE Intervention Supplement: Phase I Trial of SGT-RB94 |
| Funding Source: | NIH/NCI |
| Role: | Co-Principal Investigator |
| Principal Investigator: | Dinney |
| Duration: | 9/1/2007 - 8/31/2009 |
| Title: | Biostatics and Data Management Core |
| Funding Source: | NIH/NCI |
| Role: | Co-Program Leader |
| Principal Investigator: | Colin Dinney, MD |
| Duration: | 9/1/2006 - 8/31/2012 |
| Title: | Death Receptors in Bladder Cancer progression & Therapy |
| Funding Source: | NIH/NCI |
| Role: | Core Leader |
| Principal Investigator: | Dinney |
| Duration: | 9/25/2001 - 8/31/2012 |
| Title: | Death Receptors in Bladder Cancer Progression and Therapy |
| Funding Source: | NIH/NCI |
| Role: | Core Leader |
| Principal Investigator: | Colin P.N. Dinney |
| Duration: | 9/25/2001 - 8/31/2006 |
| Title: | Biostatics & Data Management |
| Funding Source: | NIH/NCI |
| Role: | Co-Program Leader |
| Duration: | 9/25/2001 - 8/31/2006 |
| Title: | University of Texas M.D. Anderson SPORE in Prostate Cancer |
| Funding Source: | NIH/NCI |
| Role: | Data Management Coordinator |
| Duration: | 9/25/2001 - 8/31/2006 |
| Title: | Statistical Methods for Complex Cancer Trials |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| Principal Investigator: | Peter Thall, Ph.D. |
| Duration: | 4/3/2000 - 3/31/2007 |
Last updated: 6/11/2012
- Global Navigation
- About Us
- Locations
- Calendar
- Careers
- Publications
- How You Can Help
- Contact Us
- Newsroom
- Site Index
- Patient and Cancer Information
- myMDAnderson
- Cancer Information
- Patient Information
- Care Centers & Clinics
- Children's Cancer Hospital
- Services & Amenities
- Education and Research
- Departments, Programs and Labs
- PeopleFinder
- Research at MD Anderson
- Education & Training
- Resources for Professionals
- For Employees
- Employee Alert Information
- Employee Resources
- Doing Business
- Vendors & Suppliers
- Partners & Affiliates
- Legal and Policy
- Legal Statements
- Site Policies
- Reporting Fraud, Waste & Abuse
© 2010 The University of Texas M. D. Anderson Cancer Center

